Industrial Genetics Expert to Join Intrexon
Blacksburg, Virginia, January 11, 2010 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems, today announced the appointment of Thomas J. Goralski, Ph.D., as President of its UltraVector® Division and a Senior Vice President of the corporation. Dr. Goralski will be based at Intrexon’s DNA production facility in Blacksburg, VA, which houses the company’s UltraVector® manufacturing platform and extensive inventory of modular transgene frameworks and interchangeable genetic parts.
Read Complete Press Release
Renowned Bioprocess Expert to Join Intrexon
San Francisco, California, October 28, 2009 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other life science sectors, today announced the appointment of Gerardo A. Zapata, Ph.D., as President of its Protein Production Division and a Senior Vice President of the corporation. Dr. Zapata will be based at Intrexon’s Protein Production Division headquarters in San Francisco.
Read Complete Press Release
Intrexon Announces Purchase of Industry-Leading Bioassay Operation
Blacksburg, Virginia, September 1, 2009 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned subsidiary of Clinical Data, Inc. As part of the transaction, Intrexon has purchased substantially all of the equipment and assumed the lease of Avalon’s industry-leading bioassay facility in Germantown, MD, while Clinical Data retains rights to Avalon’s intellectual property, including rights to the AvalonRx® biomarker discovery platform and oncology programs. In addition, Intrexon has entered into an agreement that enables Clinical Data to continue to advance programs that are currently in progress at the Avalon facility. A number of Avalon scientists and technicians will be joining Intrexon and continuing to work at the Maryland location.
Read Complete Press Release
Distinguished Clinical Researcher and Institute Founder Joins Intrexon as Chief Medical Officer - Oncology
Blacksburg, Virginia, August 13, 2009 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the appointment of Ronald B. Herberman, M.D., as its Chief Medical Officer - Oncology. Dr. Herberman will be responsible for overall leadership of Intrexon’s expanding anti-cancer clinical programs and related regulatory affairs.
Read Complete Press Release
Intrexon Corporation Secures Additional $10 Million of Series C-2 Investment
Blacksburg, Virginia, June 23, 2009 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, announced today it has received an additional $10 million of Series C-2 financing from New River Management V, LP, (NRM-V) a life sciences focused investment fund managed by Third Security, LLC. This is the final investment for NRM-V, which is now fully committed. Third Security intends to continue its investment strategy with a new fund, New River Management VI.
Read Complete Press Release
Intrexon Corporation Initiates Phase 1b Clinical Trial in Advanced Melanoma
Blacksburg, Virginia, May 11, 2009 – Intrexon Corporation announces that it has initiated treatment of the first patient in its Phase 1B clinical trial of INcell-1001/AD-1001 in patients with Stage III/IV melanoma. INcell-1001/AD-1001 is Intrexon’s most advanced immunomodulatory therapy. INcell-1001 is intended to control and enhance the immune-modulating performance of dendritic cells to treat solid tumor cancers. The trial is an open-label, dose-escalation study evaluating the safety, tolerance, transgene function, pharmacokinetics and immunological effects of intratumoral injection of transduced dendritic cells (INcell-1001). INcell-1001 has been engineered for inducible expression of human Interleukin 12 (hIL-12) using regimented dosing of an orally administered small molecule (AD-1001).
Read Complete Press Release
Intrexon Presents at the 27th Annual JP Morgan Healthcare Conference
Blacksburg, Virginia, January 7, 2009 – Intrexon announced today that Robert Beech, Chief Executive Officer, will be presenting the company’s latest developments at the 27th Annual JP Morgan Healthcare Conference. Intrexon’s presentation will take place on Monday, January 12, 2009 at 3:00 p.m. at the Westin St. Francis Hotel in San Francisco.
Prominent Scientist to Lead Intrexon’s Clinical Research and Development
Blacksburg, Virginia, August 25, 2008 – Intrexon, a developer of biotherapeutic control systems to enhance the safety and efficacy of existing and novel biological therapeutics, today announced the appointment of Sunil Chada, Ph.D as the Senior Vice President of Clinical Research and Development and an Officer of the Company. Dr. Chada will report directly to Intrexon’s Chief Executive Officer, Robert Beech and will be responsible for all aspects of the Company’s pre-clinical and clinical development programs.
Read Complete Press Release
Intrexon Corporation Secures $25 Million Series C-2 Investment.
Blacksburg, Virginia, May 7, 2008 – Intrexon Corporation, a privately held life sciences company focused on biotherapeutic control systems, announced today it has closed a $25 million Series C-2 financing by New River Management V, LP, a private investment fund managed by Third Security, LLC. Previous rounds of investment have been provided by New River Management IV,LP, New River Management V and NewVa Capital Partners, LP, a regional investment partnership. Funds and other entities managed by Third Security have invested a total of $56.5 million in Intrexon to date.
Read Complete Press Release